The Globe and Mail reports in its Monday, May 9, edition that Canaccord Genuity analyst Katie Lachapelle has reaffirmed her "buy" recommendation for Cameco. The Globe's David Leeder writes in the Eye On Equities column that Ms. Lachapelle trimmed her share target by a loonie to $43. Analysts on average target the shares at $42.91. Ms. Lachapelle says in a note: "We continue to believe that the company is well positioned to capitalize on growing demand for nuclear power through contracting of material from its tier-one operations. In our view, Russia's invasion of Ukraine has highlighted the importance of energy security of supply and geopolitical supply diversification in the nuclear fuel cycle. We believe Cameco is uniquely positioned with operating production facilities in North America that are not yet fully committed. As the only large capitalization, pure-play uranium producer listed in North American, Cameco remains one of our go-to-stocks for investors seeking exposure to improving uranium fundamentals and rising price." The Globe reported on Jan. 20 that CIBC began coverage of Cameco with an "outperformer" rating and $37 share target. Cameco shares could then be had for $26.80.